Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Bio-Path Holdings, Inc. is a clinical-stage biotechnology company focused on developing novel antisense oligonucleotide (ASO) therapeutics for the treatment of cancer. The company operates within the biopharmaceutical and oncology industries, with a primary emphasis on hematologic malignancies and solid tumors that are resistant to standard therapies. Bio-Path’s core strategy centers on targeting proteins that drive cancer cell survival, particularly in indications with high unmet medical need.
The company’s primary revenue drivers are research and development activities, as Bio-Path does not currently generate commercial product revenue. Its unique positioning is based on its proprietary DNAbilize® antisense technology, which is designed to improve drug stability and delivery without the use of lipid nanoparticles. Bio-Path was founded in 2007 and has evolved from a platform-focused biotechnology company into a clinical-stage developer with multiple oncology drug candidates advancing through early- and mid-stage clinical trials.
Business Operations
Bio-Path’s operations are organized around the research and development of antisense drug candidates, with its business model centered on advancing internally developed programs through clinical proof-of-concept. Its lead product candidates include prexigebersen (BP1001), targeting Grb2 for acute myeloid leukemia (AML) and other blood cancers, and BP1002, targeting Bcl-2 for AML and lymphoma. These candidates represent the company’s principal assets and account for the majority of operating expenditures.
The company conducts clinical trials primarily in the United States, working with academic cancer centers and contract research organizations. Bio-Path maintains full ownership of its core intellectual property and development programs, with no material commercial-stage joint ventures. Its operations are lean, with limited manufacturing conducted through third-party contractors and a strong reliance on external clinical and regulatory partners.
Strategic Position & Investments
Bio-Path’s strategic direction is focused on advancing its lead oncology candidates through clinical development while expanding the application of its antisense platform to additional cancer targets. Growth initiatives are primarily driven by progressing prexigebersen (BP1001) in combination regimens for AML and evaluating BP1002 in resistant hematologic cancers. The company has also explored earlier-stage programs targeting solid tumors, although these remain preclinical or inactive.
The company has not completed any transformative acquisitions and instead prioritizes organic pipeline development. Its investment strategy centers on R&D spending, intellectual property protection, and selective collaborations with academic institutions. Bio-Path’s emerging technology focus remains antisense-based cancer therapeutics, a niche segment within precision oncology that differentiates it from RNA interference and small-molecule competitors.
Geographic Footprint
Bio-Path Holdings is headquartered in Houston, Texas, and its operations are primarily based in the United States. The company’s executive leadership, research oversight, and regulatory activities are centralized at its headquarters, while clinical trials are conducted across multiple U.S. cancer treatment centers.
Internationally, Bio-Path’s footprint is limited, with no significant foreign offices or manufacturing facilities. However, its clinical trial data and intellectual property strategy are intended to support future global regulatory filings, and the company maintains patent protections in multiple jurisdictions, reflecting a long-term view toward international oncology markets.
Leadership & Governance
Bio-Path is led by an executive team with experience in biotechnology, oncology drug development, and public company governance. The leadership emphasizes capital discipline, focused clinical execution, and advancing targeted therapies for difficult-to-treat cancers.
Key executives include:
- Peter H. Nielsen – President and Chief Executive Officer
- David E. Hickerson – Chief Financial Officer
- James A. Richardson – Chief Medical Officer
- Susan L. Smith – Vice President, Regulatory Affairs
The company is governed by a board of directors with backgrounds in biotechnology, finance, and clinical medicine, supporting a strategy centered on scientific rigor, regulatory compliance, and shareholder accountability.